Printer Friendly

Actinium Pharmaceuticals Brief Report; Alpha Particles, the Cancer Killers by Small Cap Traders.

NEW YORK, Nov. 7, 2014 /PRNewswire/ -- Analyst Report by Small Cap Traders. Actinium Pharmaceuticals Incorporation (NYSEMKT: ATNM) is a public biopharmaceutical company specialized in the development of cancer drugs. The Company's product candidates are based on its patented technology co-developed with Memorial Sloan Kettering Cancer Center (MSKCC) for combining the cancer targeting precision of monoclonal antibodies (mAb) for targeting specific types of cells with the power of alpha emitting radioisotopes, the most potent cancer killing agents in existence. ATNM's technology has been also used to produce drug candidates for treatment of metastatic colorectal and prostate cancers, antiangiogenesis and bone marrow ablation, part of a curative treatment for leukemias, lymphomas and multiple myeloma.

On October 27, 2014, Actinium Pharmaceuticals and Albert Einstein College of Medicine of Yeshiva University, a research-intensive medical school in Bronx, NY, started development of an antibody construct labeled with actinium-225 using a novel technology that potentially allows for the expansion of use of the Company's proprietary platform and enables further manufacturing improvements of alpha therapy technology based drug candidates. Preclinical studies of the new technology have demonstrated significant improvements in product's manufacturing while maintaining biological integrity and properties of labeled antibodies. The new cost effective technology allows for a greater versatility in adjusting the final constructs to various clinical situations. Clinical trials of drug candidates based on alpha emitting isotopes have already demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery.

An analyst brief which covers a brief technical analysis and analyst recommendation can be viewed in its entirety by using the link below. There is no cost obligation required to view this report:

http://bit.ly/-ATNM-AnalystBrief

Copy and paste to browser may be required.

About Small Cap Traders

Once you have read our reports written by financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties.

3rd party financial analysts provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

Forward-Looking Disclaimer

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

Compliance Procedure

Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the analyst report.

If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at editor@smallcaptraders.com. For any urgent concerns or inquiries please contact us at editor@smallcaptraders.com.

Contact: editor@smallcaptraders.com

SOURCE Small Cap Traders
COPYRIGHT 2014 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Article Type:Report
Date:Nov 7, 2014
Words:648
Previous Article:Veterans Day 2014: An American Tradition in a Small French Village.
Next Article:DIFC Court Claims Jurisdiction in Indian Bank Lawsuit.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters